Pfizer keeps King tender offer open till January

Pfizer is once again extending its offer to buy King Pharmaceuticals to Jan. 21, saying about 47 percent of King shares have been tendered. Story

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.